Can antivirals help us defeat coronavirus? The odds don’t look good. The use of antiviral compounds against respiratory viruses has a chequered history. Hundreds have been tested; very few have made it to market. And even fewer make a difference. What’s more, the evidence of their impact on mortality rates – the most important outcome of all – is thin.
The race for a magic bullet to overcome Covid-19 has been going for months now. At least 254 treatments are currently undergoing development, ranging from antibodies to cell-mediated treatments. And there are over 3,500 trials underway. Twenty-five different antivirals are in various stages of development, with a variety of funders, from industry to academia to governments and private donors, often in cooperation, sometimes in competition.
In drug development, getting to the market first matters. Regardless of who funds the race, the winners (those compounds ultimately ending up with a licensed indication for use in Covid) are likely to be used in massive quantities at great expense.
Comments
Join the debate for just $5 for 3 months
Be part of the conversation with other Spectator readers by getting your first three months for $5.
UNLOCK ACCESS Just $5 for 3 monthsAlready a subscriber? Log in